



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

4th April, 2014

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Street, Fort
Mumbai 400 001.

The Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E), Mumbai 400 051.

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

Please find enclosed herewith the Press Release for your perusal.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)

Encl: a.a.



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

4th April, 2014

United States PTO Rejects Teva's '808 Patent Reissue Application on Copaxone(R) for the Second Time

NATCO Pharma today announced that the United States Patent and Trademark Office (the "PTO") issued a final office action rejecting Teva's application seeking a reissue of U.S. Patent No. 5,800,808 (the "'808 Patent"), which was found to be invalid by the Court of Appeals for the Federal Circuit in July 2013. The final rejection issued today finds the first claim of the reissue application, which is identical to the only claim in the '808 Patent, to be indefinite and both claims of the reissue application to be unpatentable based on obvious-type double patenting. In its ruling, the PTO refused to extend patent protection on Copaxone(R) past the patents that will expire in May 2014.

NATCO is pleased that the PTO has rejected the reissue application, confirming the indefiniteness for the second time and consistent with the Federal Circuit's decision, and that the PTO continues to find all claims to be unpatentable.

For NATCO Pharma Limited

M. Adinarayana

M. Adinarayana

Company Secretary &
Vice President (Legal & Corp Affairs)